Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
International Journal of Dermatology|February 15, 2026
Optimizing Local Treatment in Pemphigus and Pemphigoid: Current Evidence and Unmet NeedsRoberto Maglie, Dario Didona, Maria Chiara Collina, et al.Nutrients|November 13, 2025
Mediterranean Diet Adherence, Sleep Disturbances and Emotional Well-Being in Skin Ulcer Burden: Insights from a Monocentric RegistryTonia Samela, Giulia Raimondi, Damiano Abeni, et al.Frontiers in Bioengineering and Biotechnology|May 19, 2022
Innovative Cell and Platelet Rich Plasma Therapies for Diabetic Foot Ulcer Treatment: The Allogeneic ApproachMaddalena Mastrogiacomo, Marta Nardini, Maria Chiara Collina, et al.Scientific Reports|November 11, 2024
The healing process of diabetic ulcers correlates with changes in the cutaneous microbiotaEmanuele Bruni, Giovanni Luca Scaglione, Denise Tampone, et al.European Journal of Dermatology : EJD|November 24, 2025
Localized dominant dystrophic epidermolysis bullosa worsened by diabetesAlessia Primerano, Giovanna Floriddia, Emanuela De Domenico, et al.International Wound Journal|March 7, 2026
Neoplastic Foot Ulcers: A Multicentre Retrospective StudyAgata Janowska, Valentina Dini, Marco Romanelli, et al.HLA|August 2, 2024
HLA alleles associated to susceptibility to gliptin-associated bullous pemphigoid in Italian patientsMarco Andreani, Feliciana Mariotti, Anna Pira, et al.Drug Design, Development and Therapy|July 21, 2021
A Call to Action by the Italian Mesotherapy Society on Scientific ResearchMassimo Mammucari, Teresa Paolucci, Domenico Russo, et al.Journal of the American Academy of Dermatology|May 22, 2026
Linagliptin is a risk factor for bullous pemphigoid associated with BP180-NC16A/BP230 seronegativity and milder severity: evidence from a prospective case-control study supporting ECD-BP180 ELISA in reducing diagnostic delayAnna Pira, Adele Salemme, Feliciana Mariotti, et al.Pageof 1